A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.

YuJung Kim,Bhumsuk Keam,Chan-Young Ock,Sanghoon Song,Miso Kim,Se-Hyun Kim,Ki Hwan Kim,Jin Soo Kim,Tae Min Kim,Dong-Wan Kim,Jong Seok Lee,Dae Seog Heo

A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.

2018

YuJung Kim
Bhumsuk Keam
Chan-Young Ock
Sanghoon Song
Miso Kim
Se-Hyun Kim
Ki Hwan Kim
Jin Soo Kim
Tae Min Kim
Dong-Wan Kim
Jong Seok Lee
Dae Seog Heo

8575Background: Patients with platinum refractory extensive disease (ED) small cell lung cancer (SCLC) have a poor prognosis and a little progress have been made. We aimed to investigate the effica...

Keywords:

Refractory
Extensive Disease
Cell
Oncology
Phases of clinical research
Pathology
Lung cancer
Paclitaxel
Pembrolizumab
Internal medicine
Medicine
platinum resistance
non small cell
poor prognosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations